Breast Cancer Research This program is focused upon making improvements in breast cancer patient regimens and outcomes, using an interdisciplinary approach. Our program hopes to achieve this goal by utilizing an improved understanding of the distinct biology of the intrinsic subtypes of breast cancer and breast cancer heterogeneity obtained through tissue-based studies, with additional biomarker discovery and validation, risk factor appraisal, and drug development, which lead to new therapeutic trials and population-based studies. Specifically, our strategic goals are: 1) basic and epidemiologic science discovery integrated with our existing understanding of the intrinsic breast cancer subtypes, 2) technological advances in imaging and therapy, 3) mouse models testing of promising therapeutic approaches in models representing the known biological subtypes, and 4) tissue-based discovery and clinical research algorithms for rational drug/combination studies with bidirectional strategies of containing embedded correlative/research biopsy studies. The Breast program is well suited to foster translation of basic science findings Into the clinic and back again because it is heavily integrated into a very active multidisciplinary clinical and clinical-translational operation, n addition, this program is seamlessly integrated with our mature breast cancer SPORE infrastructure that includes clinicians, epidemiologists, and laboratory scientists. Highlights of research by program investigators include development of genetically engineered mouse models representing many of tine intrinsic subtypes allowing subtype-specific therapeutic strategies to be tested in the mouse phase I unit (Perou, Sharpless), the development of anotechnology-based and other novel imaging that can be applied to both small animal and human breast cancers (Zhou, Pisano), and the design and execution of clinical trials using novel regimens and trial designs (Carey, Anders);the clinical focus remains on the manage of subtype-specific prospective clinical trials with targeted agents and embedded correlative analysis of molecular signatures and cross-trial validations. Substantial progress in understanding the risk factors and molecular biology of specific intrinsic subtypes has come from collaborations between faculty from the schools of Medicine, Public Health, and Genetics, including the first identification of the association of basal-like breast cancer with African-American women (Carey, Perou, MiDikan). The population-based Carolina Breast Cancer Study III is integral to this program and is examining subtype-specific risk factors and outcomes with a focus upon African-American women. Complementary studies are examining epigenetic and microenvironmental influences (Troester, Swift-Scanlan) that should address the """"""""soil"""""""" contributions to these risks, and a new program in geriatric oncology is focusing upon molecular correlates of breast tumor and host response to therapy (Muss, Sharpless). The Program consists of 24 members from five different schools and clinicians from five different disciplines. In 2009, Breast Research Program members held 56 grants and $12.3M (total cost) in annual extramural funding, including 24 grants and $7.4M (total costs) from the NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-36
Application #
8376335
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
36
Fiscal Year
2012
Total Cost
$186,853
Indirect Cost
$76,454
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Conway, Kathleen; Edmiston, Sharon N; Parrish, Eloise et al. (2017) Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study. Breast Cancer Res Treat 163:349-361
Williams, Lindsay A; Olshan, Andrew F; Hong, Chi-Chen et al. (2017) Alcohol Intake and Breast Cancer Risk in African American Women from the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 26:787-794
Quach, Bryan; Furey, Terrence S (2017) DeFCoM: analysis and modeling of transcription factor binding sites using a motif-centric genomic footprinter. Bioinformatics 33:956-963
Wang, Sheng; Wacker, Daniel; Levit, Anat et al. (2017) D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358:381-386
Westmoreland, Katherine D; Montgomery, Nathan D; Stanley, Christopher C et al. (2017) Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi. Int J Cancer 140:2509-2516
Kang, SunAh; Fedoriw, Yuri; Brenneman, Ethan K et al. (2017) BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis. J Immunol 198:2602-2611
Ehe, Ben K; Lamson, David R; Tarpley, Michael et al. (2017) Identification of a DYRK1A-mediated phosphorylation site within the nuclear localization sequence of the hedgehog transcription factor GLI1. Biochem Biophys Res Commun 491:767-772
Krishnaiah, Saikumari Y; Wu, Gang; Altman, Brian J et al. (2017) Clock Regulation of Metabolites Reveals Coupling between Transcription and Metabolism. Cell Metab 25:961-974.e4
Shutova, Maria S; Asokan, Sreeja B; Talwar, Shefali et al. (2017) Self-sorting of nonmuscle myosins IIA and IIB polarizes the cytoskeleton and modulates cell motility. J Cell Biol 216:2877-2889
Evon, Donna M; Golin, Carol E; Stewart, Paul et al. (2017) Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials 57:58-68

Showing the most recent 10 out of 1197 publications